Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocks
AJANTPHARM
AJANTPHARM
3,480.00+9.6 (+0.28%)
7 Aug, 12:00 AM

Stock Scores

Quality Score

90.0 / 100

Value Score

23.2 / 100

Price Momentum Score

87.1 / 100

QVM Score

83.0 / 100

Key Metrics

Market Cap
43485.70
P/E (TTM)
38.32
P/B
9.61
P/S (TTM)
7.53
EV/EBITDA
28.00
CAPE (5Y)
51.65
ROE (TTM)
25.39
ROCE (TTM)
30.76
ROA (TTM)
18.91
Avg 3Y ROE
24.63
Earnings 3Y CAGR
23.02
Sales 3Y CAGR
14.85
Sales 5Y CAGR
14.23
Debt/Equity
0.06
Consensus TP
3787.00
Strong Buy %
40.00
Promoter Holding
63.48
Pledged %
22.53

Share Price

Track Ajanta Pharma Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.

3,480.009.6 (0.28%)
33.56% in past 1 year
1 Week returns: 0.43 %
Low
3,403.1
High
3,550.0
1 Month returns: 4.98 %
Low
3,254.8
High
3,598.8
1 Year returns: 32.87 %
Low
2,329.9
High
3,598.8
3 Year CAGR: 25.59 %
Low
1,650.1
High
3,598.8
5 Year CAGR: 17.86 %
Low
1,061.8
High
3,598.8
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.

Stock Analysis

Fundamental analysis overview of Ajanta Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views
Red Flags
Positive
Strong price momentum

Price Momentum score of 87.1 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

87.1 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 0.87% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

98.5Mar 2698.5Apr 2699.93May 26101.14Jun 26102.97Jul 26104.03Aug 26
High and stable ROE

The company reported strong ROE of 25.39% for 12-month ended 30 Jun 2026 and ROE improved marginally by 37 bps from 1 year ago

What is ROE (FY)?

High and stable operating margin

The company reported strong operating margin of 23.58% for 12-month ended 30 Jun 2026 and operating margin declined marginally by -97 bps from 1 year ago

What is Operating profit margin?

Strong revenue growth and above median growth of industry

The company delivered strong revenue growth of 20.19% for 12-month ended 30 Jun 2026 and the growth was 8.26 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 11.93
Value 20.19
-42.89239.3
Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 22.22% for 12-month ended 30 Jun 2026 and the growth was 8.94 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.06 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.05 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 8 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative
Expensive and at a premium to industry median P/E

PE TTM of 38.32 indicates that the stock is expensive on a standalone basis and is at a 25.27% premium to industry median P/E

What is P/E Ratio?

Median: 30.59
Value 38.32
0.33286.35
Low dividend yield

The company has a low dividend yield of 0.8%

What is Dividend yield?

Neutral
Company's earnings are of moderate quality

Earnings quality score of 46.2 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

46.2 / 100

No red flags found!
No significant red flags found in the stock.

Financial Snapshot

See detailed analysis

Multi-year trends for Ajanta Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY
02k4k6k3.7 K CrMar 20234.2 K CrMar 20244.6 K CrMar 20255.5 K CrMar 2026
Profit After Tax FY
01k1k2k588.0 CrMar 2023816.2 CrMar 2024920.4 CrMar 20251.1 K CrMar 2026
ROE FY
0%10%20%30%17.7%Mar 202323.5%Mar 202425.0%Mar 202525.4%Mar 2026
EBITDA FY
01k1k2k810.9 CrMar 20231.2 K CrMar 20241.3 K CrMar 20251.5 K CrMar 2026

Ajanta Pharma Ltd. Shareholding Pattern

Quarterly breakdown of Ajanta Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Promoter
70.50
70.51
70.51
70.34
70.34
70.34
70.34
70.34
70.48
70.48
70.48
66.11
66.11
66.21
66.21
66.21
66.21
66.27
66.26
66.26
66.26
66.26
66.25
66.25
66.25
63.48
Indian Promoter
70.50
70.51
70.51
70.34
70.34
70.34
70.34
70.34
70.48
70.48
70.48
66.11
66.11
66.21
66.21
66.21
66.21
66.27
66.26
66.26
66.26
66.26
66.25
66.25
66.25
63.48
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
20.28
20.00
19.90
20.38
20.99
21.18
21.22
21.54
21.38
21.21
21.36
25.89
25.98
26.00
25.58
25.78
26.03
25.78
26.22
26.29
26.35
26.37
26.44
26.57
26.64
29.48
Mutual Funds / UTI
9.25
9.51
9.93
9.78
9.53
9.95
10.26
10.74
10.50
10.88
11.14
13.57
13.77
13.07
12.84
13.86
14.76
14.84
14.93
14.89
15.13
14.72
14.67
15.49
15.22
18.10
FI/Bank/Insurance
0.62
0.84
0.69
1.08
1.35
1.09
1.25
0.81
1.11
1.04
1.01
1.28
1.30
1.64
2.07
2.15
2.16
2.20
1.57
1.48
1.58
2.01
2.64
2.65
2.70
3.29
Govt
0.74
0.74
0.75
0.76
0.76
0.43
0.43
0.45
0.45
0.45
-
-
-
-
-
-
-
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
-
FII
8.91
8.23
7.71
7.90
8.37
8.94
8.72
8.95
8.64
8.30
8.23
10.07
10.00
10.19
9.99
9.11
8.54
8.36
9.11
9.26
8.86
8.86
8.53
7.97
8.26
7.68
Other Institutions
0.76
0.68
0.80
0.85
0.98
0.78
0.56
0.59
0.67
0.54
0.98
0.97
0.90
1.11
0.69
0.66
0.56
0.37
0.59
0.65
0.77
0.77
0.59
0.44
0.44
0.41
Non-Institution
9.21
9.49
9.59
9.27
8.67
8.47
8.43
8.12
8.14
8.31
8.15
8.00
7.91
7.79
8.20
8.01
7.76
7.94
7.52
7.45
7.39
7.38
7.32
7.19
7.12
7.03
Bodies Corporate
0.54
0.41
0.34
0.33
0.33
0.11
0.28
0.25
0.25
0.24
0.24
0.28
0.22
0.25
0.30
0.28
0.24
0.25
0.21
0.19
0.17
0.22
0.18
0.17
0.17
0.17
Others (incl. Retail)
No. of shareholders
8.67
38,585
9.08
45,635
9.25
48,248
8.94
48,883
8.34
44,280
8.36
45,277
8.15
51,557
7.87
57,081
7.89
59,899
8.07
63,545
7.91
61,132
7.72
58,861
7.69
82,667
7.54
54,008
7.90
55,383
7.73
53,464
7.52
54,648
7.69
69,430
7.31
63,403
7.26
65,936
7.22
69,874
7.16
67,978
7.14
66,926
7.02
64,611
6.95
67,117
6.86
64,452

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence
#IndexWeightRank
1Nifty Pharma1.56%18 / 20
2Nifty 500 Momentum Quality 500.84%34 / 50
3Nifty Midcap 150 Momentum 500.6%46 / 50
4Nifty Midcap 1500.35%111 / 149
5NIFTY Large Midcap 2500.18%178 / 250
6Nifty 5000.07%245 / 499
7Nifty Total Market0.07%250 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Ajanta Pharma Ltd. shares as reported to NSE and BSE.

NameMonthTransactionHolding % pre transactionAverage priceQty.Transaction value
SHAILESH R SINGH
Designated Person
March-2026
Market Sale (Disposal)
13th Mar 2026
0.01 %₹ 3,100.18607.00₹ 18.82 lac
SHAILESH R SINGH
Designated Person
December-2025
Market Sale (Disposal)
29th Dec 2025
0.01 %₹ 2,713.08750.00₹ 20.35 lac
SHAILESH R SINGH
Designated Person
November-2025
Market Sale (Disposal)
13th Nov 2025
0.01 %₹ 2,565.412.00 k₹ 51.31 lac
SHAILESH R SINGH
Designated Person
November-2025
Market Sale (Disposal)
13th Nov 2025
0.02 %₹ 2,528.433.00 k₹ 75.85 lac
SHAILESH R SINGH
Designated Person
June-2025
Market Sale (Disposal)
26th Jun 2025
0.02 %₹ 2,574.43900.00₹ 23.17 lac
VANDANA SHAILESH SINGH
Designated Person
February-2025
Market Sale (Disposal)
28th Feb 2025
0.00 %₹ 2,722.45548.00₹ 14.92 lac
J K TRIPATHI
Designated Person
December-2024
Market Sale (Disposal)
31st Dec 2024
0.00 %₹ 2,950.00100.00₹ 2.95 lac
J K TRIPATHI
Designated Person
December-2024
Market Sale (Disposal)
31st Dec 2024
0.00 %₹ 2,895.00100.00₹ 2.90 lac
J K TRIPATHI
Designated Person
December-2024
Market Sale (Disposal)
31st Dec 2024
0.00 %₹ 3,000.00100.00₹ 3.00 lac
J K TRIPATHI
Designated Person
December-2024
Market Sale (Disposal)
31st Dec 2024
0.00 %₹ 3,060.0049.00₹ 1.50 lac
…

Corporate Actions

History of Ajanta Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

  • Dividend₹ 32/share
    Record date: 5th Aug 2026Ex-date: 5th Aug 2026
    Announced on: 20th Jul 2026
  • Dividend₹ 28/share
    Record date: 10th Nov 2025Ex-date: 10th Nov 2025
    Announced on: 24th Oct 2025
  • Dividend₹ 28/share
    Record date: 6th Nov 2024Ex-date: 6th Nov 2024
    Announced on: 23rd Oct 2024
  • Others
    Ex-date: 30th May 2024Announced on: 2nd May 2024
    "On Market Tender offer. As on 27 June 2024 Total shares repurchased 1028881."
  • Dividend₹ 26/share
    Record date: 8th Feb 2024Ex-date: 8th Feb 2024
    Announced on: 25th Jan 2024

Company Profile

Overview of Ajanta Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of...
Key personnel
Mr. Arvind K. Agrawal
Chief Financial Officer
Mr. Gaurang C. Shah
Vice President - Legal, Company Secretary
Mr. Mannalal Bhagwandas AgrawalD
Non-Executive Chairman of the Board
Mr. Madhusudan Bhagwandas AgrawalD
Executive Vice Chairman of the Board
Mr. Rajesh Mannalal AgrawalD
Joint Managing Director, Executive Director
Mr. Yogesh Mannalal AgrawalD
Managing Director, Executive Director
Mr. Rajesh Shashikant DalalD
Non-Executive Independent Director
Mrs. Medha Vinay JoshiD
Non-Executive Independent Director
View all
Incorporated on
31 Dec 1979
Last Annual
31 Mar 2026
Last Interim
30 Jun 2026
No. of Employees
10,421
IPO date
05 Jun 2000
Free Float
4,55,12,335
Phone no.
+912266061000
Address
Ajanta House,, Charkop, Kandivli West,, MUMBAI, 400067, India

Frequently Asked Questions

What is the current share price of Ajanta Pharma Ltd.?
The current share price of Ajanta Pharma Ltd. is ₹ 3,480.00 as of 7 Aug 2026.
What is the market capitalisation of Ajanta Pharma Ltd.?
The market capitalisation of Ajanta Pharma Ltd. stands at ₹ 43,485.70 Cr.
What is the PE ratio of Ajanta Pharma Ltd.?
The Price-to-Earnings (PE) ratio of Ajanta Pharma Ltd. is 38.32 as of the latest trailing twelve months data.
What is the ROE and ROCE of Ajanta Pharma Ltd.?
Ajanta Pharma Ltd. has a Return on Equity (ROE) of 25.39% and a Return on Capital Employed (ROCE) of 30.76% as per the latest financial reports.
What is the 52-week high and low of Ajanta Pharma Ltd.?
The 52-week high of Ajanta Pharma Ltd. is - and the 52-week low is -.
What is the dividend yield of Ajanta Pharma Ltd.?
The dividend yield of Ajanta Pharma Ltd. is 0.80% based on the current market price.
What is the FII and DII holding in Ajanta Pharma Ltd.?
Foreign Institutional Investors (FII) hold 7.68%, Domestic Institutional Investors (DII) hold 21.39% and retail/public investors hold 6.86% of Ajanta Pharma Ltd. shares.
What sector does Ajanta Pharma Ltd. belong to?
Ajanta Pharma Ltd. operates in the Healthcare sector. 66.67% of analysts have a Buy or Strong Buy rating on Ajanta Pharma Ltd. with a consensus target price of ₹ 3,787.00, implying 8.82% upside from current levels.
What is the beta of Ajanta Pharma Ltd.?
The beta of Ajanta Pharma Ltd. is 0.52, indicating its price volatility relative to the broader market. Over the past 1 year, Ajanta Pharma Ltd. has delivered an absolute return of 24.26%.
What is the RSI of Ajanta Pharma Ltd.?
The 14-day Relative Strength Index (RSI) of Ajanta Pharma Ltd. is 57.63, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.